MaxCyte Inc MXCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
-
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
-
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
-
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
Trading Information
- Previous Close Price
- GBX 284.00
- Day Range
- GBX 280.00–287.00
- 52-Week Range
- GBX 170.00–430.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 29.85 Bil
- Volume/Avg
- 2,089 / 14,015
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.18
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 143
- Website
- https://www.maxcyte.com
Comparables
Valuation
|
Metric
|
MXCT
|
VICP
|
219A
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.70 | — | — |
Price/Sales | 8.18 | — | 105.92 |
Price/Cash Flow | — | — | — |
Price/Earnings
MXCT
VICP
219A
Financial Strength
|
Metric
|
MXCT
|
VICP
|
219A
|
|---|---|---|---|
Quick Ratio | 13.19 | 0.03 | 17.28 |
Current Ratio | 14.31 | 0.14 | 18.22 |
Interest Coverage | — | — | −1,951.59 |
Quick Ratio
MXCT
VICP
219A
Profitability
|
Metric
|
MXCT
|
VICP
|
219A
|
|---|---|---|---|
Return on Assets (Normalized) | −8.16% | −297.04% | −25.34% |
Return on Equity (Normalized) | −9.30% | — | −27.01% |
Return on Invested Capital (Normalized) | −13.01% | — | −26.88% |
Return on Assets
MXCT
VICP
219A
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Wwsjfwml | Wzyjhrl | $196.0 Bil | |||
| Stryker Corp
SYK
| Krdvwlvht | Rxmgl | $133.8 Bil | |||
| Boston Scientific Corp
BSX
| Ftdnrqp | Wskmnv | $124.5 Bil | |||
| Medtronic PLC
MDT
| Wkhzdkjrz | Kpfjgg | $113.2 Bil | |||
| Edwards Lifesciences Corp
EW
| Kcktbvjg | Mxxlcn | $39.5 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Hdhnn | Ydd | $30.2 Bil | |||
| DexCom Inc
DXCM
| Ycknntlsd | Tgsy | $27.3 Bil | |||
| Steris PLC
STE
| Znszcqxjp | Kwpqvpx | $22.8 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Ygbtydwcfp | Bph | $21.3 Bil | |||
| Insulet Corp
PODD
| Lqhvzlgvt | Pqqdcrk | $16.1 Bil |
United States